CDC42 and atherosclerosis: (3) CDC42 might slow the progression of SV-CAD by suppressing atherosclerosis, inflammation, and dyslipidemia; meanwhile, multivessel disease and ACC/AHA type B2/C lesions represented more complex coronary artery lesions and worse disease progression in DCB-treated SV-CAD patients [29–31].